ID: MRFR/Pharma/4475-HCR | 100 Pages | Author: Rahul Gotadki | June 2023
The Chronic Idiopathic Constipation Market is anticipated to reach USD 9,257 Million by 2030 at 7.3% CAGR during the forecast period 2022-2030.
Chronic idiopathic constipation is understood and referred to as an extremely widespread functional bowel disorder that causes distress amongst millions of people around the globe, especially during the forecast period. Some of the major features of the market that are contributing to the growing number of patients that are suffering from chronic idiopathic constipation include a sedentary lifestyle, a severe decrease in the intake of dietary fibers, and the rise in usage of anti-inflammatory agents.
COVID 19 Analysis
The COVID-19 pandemic has broken the internet and market trends and has circulated new opportunities and challenges. The pandemic is an incomparable global public health emergency. The arrival of the pandemic has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period that will be ending in 2028. The research analyst's ongoing research amplifies their research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report discusses that the outbreak of the pandemic has forced people to bring about a change in their lifestyle and consumer preferences. The pandemic has further forced the global governments and public sector to take important steps like lockdown and strict measures that will impact the market and the demand that might result in losses during the forecast period that will be ending in 2028.
The government and market players are understanding the need to return to normalcy to keep the market functioning with the rising competition in the global market premises. The chronic idiopathic constipation market trends are expected to rise with the enhanced research and development initiatives that are prevailing in the global market premises amid the duration of the current forecast period of 2021-2028.
Major factors that are expected to boost the growth of the chronic idiopathic constipation market in the forecast period are the rise in the aging population. The rising ease and accessibility of over-the-counter drugs for chronic idiopathic constipation is further anticipated to propel the growth of the global market. On the other hand, the accessibility of substitute treatments is further projected to impede the growth of the chronic idiopathic constipation market in the timeline period that will be ending in 2028.
However, the chronic idiopathic constipation market size is witnessing a decrease in the diverse need for healthcare expenditure in a few advancing and developing countries that might further challenge the growth of the chronic idiopathic constipation market as expected shortly, especially during the ongoing forecast period that will be ending in 2028.
The target audience across the world is known to have accepted living a sedentary lifestyle alongside a severe degree of decrease in the intake of dietary fibers that are impacting the people and hence, giving rise to the chronic idiopathic constipation market. Also, the market trends show that there has been a rising degree of use for anti-inflammatory agents and agencies. The technological availability is welcoming the investments from various domestic and international companies and governments that are likely to provide the market with a good fortune and expansion rate during the ongoing forecast period that will be ending in 2028.
The chronic idiopathic constipation market dynamics predict a good fortune for the market amid the rising market trends. The market is being recorded to perform at an excellent scale based on the global segmentation that is as follows:
Based on the diagnosis
The chronic idiopathic constipation market is segmented based on the diagnosis and includes blood tests, sigmoidoscopy, colonoscopy, balloon expulsion test, anorectal manometry, colonic transit study, defecography, and others.
Based on the treatment
The chronic idiopathic constipation market is segmented based on the treatment and includes drugs and surgery. Drugs have further been segmented into acid neutralizers, laxatives and antidiarrheal, antiemetics, antiulcer, lubiprostone (amitiza), and linaclotide (linzess), misoprostol (Cytotec), colchicine/probenecid (Col-Probenecid) alongside others like Onabotulinumtoxin A (also called botulinum toxin type A or Botox).
Based on the end-user industries
The chronic idiopathic constipation market is segmented based on the end-user industries and includes hospitals, gastroenterology clinics, diagnostic centers, and others.
The North American chronic idiopathic constipation market has been segmented into two domestic regions, namely, North America and South America. The North American region, being the largest market, is witnessing major growth trends during the forecast period ending in 2028. The growth is mainly driven due to the substantial increase in the prevalence of chronic constipation and the growing investment in the healthcare departments and infrastructure. Also, the U.S., as a part of North America is the largest market in the North American region owing to the huge and evolving presence of a large number of market players who are indulged in the manufacturing of medications for constipation.
The global rise in the market premises during the ongoing forecast period of 2021-2028 is because of the splendid record and performance of the prominent players of the market that are stated as follows:
The chronic idiopathic constipation market report is focusing on the market developments for the period that will lead the way of the market towards growth during the forecast period that will be ending in 2028. The market report covers the basis of the market segmentation and the rising market potential to meet the needs of the target audience during the period.
|Market Size||USD 9,257 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Diagnosis, Treatment, and End-user|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Actavis (U.S.), Chugai Pharmaceutical (Japan), Ferring International Center S.A.(Switzerland), Synergy Pharmaceuticals (U.S.), Pfizer Inc (U.S.), GlaxoSmithKline (U.K.), Sanofi (France), Bayer (Germany), Salix Pharmaceuticals Ltd (U.S.), Sucampo Pharmaceuticals Inc (U.S.), Ironwood Pharmaceuticals (U.S.), Progenics Pharmaceuticals (U.S.), F. Hoffmann-La Roche AG (Switzerland), Boehringer Ingelheim GmbH (Germany), Daewoong Co. Ltd.(South Korea), Synergy Pharmaceuticals, Inc. (U.S.) and others|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
Chronic idiopathic constipation market is expected to expand at 7.3% CAGR from 2022-2030.
Early detection of GI diseases at a preventive stage is the primary driver of the global chronic idiopathic constipation market.
Low awareness of the treatment is the major factor expected to impede the global chronic idiopathic constipation market growth.
The Americas is expected to dominate the global chronic idiopathic constipation market till 2030 due to large number of cases of chronic constipation.
Pfizer Inc, Salix Pharmaceuticals Ltd, Bayer, Sucampo Pharmaceuticals Inc, GlaxoSmithKline, Ironwood Pharmaceuticals, Chugai Pharmaceutical, Synergy Pharmaceuticals, Boehringer Ingelheim GmbH, Progenics Pharmaceuticals, F. Hoffmann-La Roche AG, Daewoong Co. Ltd., Actavis, Synergy Pharmaceuticals, Inc., Ferring International Center S., and Sanofi are prominent players of the global chronic idiopathic constipation market.
Key Questions Answered
Why Choose Market Research Future?